Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical, Inc. (Nasdaq: AEMD) reported its financial results for the second quarter ended September 30, 2021, highlighting ongoing developments for the Hemopurifier™, a blood filtration system targeting COVID-19 and cancer. As of September 30, the company had $23.2 million in cash and generated $132,000 in government contract revenue, compared to none in the same quarter last year. Operating expenses rose to $2.1 million, resulting in a net loss of approximately $2.0 million. The company is advancing U.S. clinical trials and has expanded its international presence with a trial in India.
Aethlon Medical (AEMD) will announce its second quarter fiscal year 2022 financial results on November 9, 2021, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST, where management will discuss the financial results and corporate developments. The Hemopurifier, Aethlon's lead technology, targets life-threatening infections and cancer, and has received FDA Breakthrough Device designation. The company is conducting an Early Feasibility Study at the University of Pittsburgh to evaluate the Hemopurifier's effects on cancer-associated exosomes.
Aethlon Medical, Inc. (AEMD) has published a manuscript in Frontiers in Medicine detailing two case studies of critically ill COVID-19 patients treated with the Hemopurifier® blood filtration system. The study shows the Hemopurifier®'s ability to remove SARS-CoV-2 virus, exosomes, and exosomal microRNAs, with one patient experiencing clinical improvement. The device is undergoing an Early Feasibility Study to evaluate its safety in treating up to 40 COVID-19 ICU patients. Aethlon holds FDA Breakthrough Device designations for its applications in cancer and life-threatening viral diseases.
Aethlon Medical, Inc. (Nasdaq: AEMD) has announced a partnership with PPD, Inc. (Nasdaq: PPD) to manage clinical studies for its Hemopurifier, a therapeutic blood filtration system focused on treating infectious diseases, including COVID-19. Under this agreement, PPD will oversee ongoing clinical trials and may expand to additional studies. The Hemopurifier has received FDA Breakthrough Device designation and has shown promise in removing harmful viruses and exosomes in prior studies. This collaboration aims to expedite the clinical development for critically ill patients.
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. CEO Charles J. Fisher will offer an overview on September 13 at 7:00 AM EDT, available on-demand for 90 days. Aethlon’s Hemopurifier, a clinical-stage device for treating cancer and viral infections, holds FDA's Breakthrough Device designation. The company also operates Exosome Sciences, focused on exosomal biomarkers for cancer and neurological diseases.
Aethlon Medical, Inc. (Nasdaq: AEMD) reported financial results for Q1 ended June 30, 2021, highlighting continued clinical development of the Hemopurifier for COVID-19. The company raised $17.5 million from common stock sales, bringing cash reserves to $25.2 million. Total government contract revenue was approximately $132,000. Operating expenses increased to $2.2 million, leading to a net loss of $2.1 million, up from $1.4 million year-over-year. The company is negotiating with additional clinical centers for trials, with a focus on potential treatments for SARS-CoV-2.
Aethlon Medical, Inc. (AEMD) will announce its first quarter fiscal year 2022 financial results on August 9, 2021, at 4:15 p.m. EST. This will be followed by a conference call at 4:30 p.m. EST to discuss the results and recent corporate developments. The company is known for its Hemopurifier®, a medical device addressing unmet global health needs, particularly in cancer treatment and life-threatening viral infections like COVID-19. The Hemopurifier has received FDA 'Breakthrough Device' designation, allowing for innovative clinical applications and studies.
Aethlon Medical (AEMD) reported financial results for the fiscal year ended March 31, 2021, highlighting a net loss of approximately $7.9 million, up from $6.4 million the previous year. Operating expenses increased to about $8.6 million, driven by higher payroll and clinical trial costs. The company raised around $17.3 million in June 2021 through various financing methods. The Aethlon Hemopurifier showed potential in treating COVID-19 patients, with successful case studies reported. As of March 31, 2021, cash reserves stood at about $9.9 million.
Aethlon Medical (AEMD) will release its financial results for Q4 fiscal year 2021 on June 24, 2021, at 4:15 p.m. ET. Management will also host a conference call at 4:30 p.m. ET the same day to discuss the results and corporate developments. The Hemopurifier, the company’s clinical-stage device, aims to treat cancer and viral infections. It holds FDA designations as a Breakthrough Device for advanced cancer and life-threatening viral infections, including COVID-19.
Aethlon Medical, Inc. (Nasdaq:AEMD) announced a registered direct offering of 1,380,555 shares at $9.00 per share, totaling approximately $12.425 million in gross proceeds. The offering is expected to close on June 14, 2021. Proceeds will be used for working capital and general corporate purposes. Additionally, Aethlon sold 626,000 shares under its At the Market Offering Agreement and will issue 1.12 million shares due to warrant exercises. The Hemopurifier, a key product, is in clinical trials for cancer treatment and COVID-19.
